Experience of a medicines reference-pricing model

South African Medical Journal

Volumn 94, Issue 3 I, 2004, Pages 183-188

  Rothberg, A D ^a   Blignault, J ^a   Serfontein, C B ^b   Valodia, B ^a   Eekhout, S ^a   Pels, L M ^a  

^a Medscheme Pty Ltd   (South Africa)

^b Interpharm Pty Ltd   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; SIMVASTATIN;

ARTICLE; DRUG COST; DRUG INDUSTRY; DRUG MONITORING; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH PRACTITIONER; HEALTH PROGRAM; HEALTH SERVICE; PHARMACY; PROFESSIONAL PRACTICE; PROSPECTIVE STUDY; PUBLICATION; REIMBURSEMENT; RETROSPECTIVE STUDY;

COST SAVINGS; DEVELOPING COUNTRIES; DRUG COSTS; DRUGS, GENERIC; HUMANS; INFLATION, ECONOMIC; INSURANCE, PHARMACEUTICAL SERVICES; MANAGED CARE PROGRAMS; MODELS, ECONOMETRIC; PRESCRIPTIONS, DRUG; PROGRAM EVALUATION; RISK ASSESSMENT; SOCIOECONOMIC FACTORS; SOUTH AFRICA;

EID: 1642416864     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Kanavos P. Financing pharmaceuticals in transition economies. Croat Med J 1999; 40: 244-259.
2. Grootendorst PV, Dolovich LR, O'Brien BJ, Holbrook AM, Levy AR. Impact of reference-band pricing of nitrites on the used and costs of anti-anginal drugs. CMAJ 2001; 165: 1011-1019.
3. Marshall JK, Grootendorst PV, O'Brien BJ, Dolovich LR, Holbrook AM, Levy AR. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. CMAJ 2002; 166: 1655-1662.
4. Schneeweiss B, Sonmerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilisation. CMAJ 2002; 166: 763-764.
5. Towse A. The efficient use of pharmaceuticals: Dose Europe have any lessons for a Medicare drug benefit. Health Aff 2003; 22: 42-45.
6. Mrazek MF. Comparative approaches to pharmaceutical price regulation price regulation in the European Union. Croat Med J 2002; 43: 453-461.
7. Ioannides-Demos LL, Ibrahim JE, McNeil JJ. Reference-based pricing schemes: Effect on pharmaceutical expenditure, resource allocation and health outcomes. Pharmacoeconomics 2002; 20: 577-591.
8. Olson BA. Approaches to pharmacy benefit management and the impact of consumer cost sharing. Clin Ther 2003 25: 250-272.
9. Dietz MS, Schneeweiss S, Maclure M, Abel T, Glynn RJ, Sonmerai SB. Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia. Clin Ther 2003; 25: 273-284.
10. Morgan SG. Quantifying components of drug expenditure inflation: The British Columbia senior's drug benefit plan. Health Serv Res 2002; 37: 1243-1266.
11. Drummond M, Jonsson B, Rutter F. The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 1997; 40: 199-215.
12. De Vos CM. The 1996 pricing and reimbursement policy in The Netherlands. Pharmacoeconomics 1996; 10: Suppl 2, 75-80.
13. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003; 21: 89-103.
14. Darba J, Rovira J. Parallel impacts of pharmaceuticals in the European Union. Pharmacoeconomics 1998; 14: Suppl, 129-136.